Chemours Company (The) (CC) Earnings Date & Reports

Key Takeaways

• Third-quarter 2026 net sales rose 3% year over year to $1.54 billion, essentially in line with analyst estimates.
• Adjusted (non-GAAP) earnings per share (EPS) came in at $0.21, up 24% from $0.17 a year earlier but below the consensus estimate.
• GAAP diluted EPS of $1.29 was inflated by $150 million in PFAS insurance proceeds and a gain on the sale of the Kuan Yin property, and does not reflect underlying operating trends.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $200 million, up from $189 million, driven by strong pricing in the Titanium Technologies segment.
• Thermal & Specialized Solutions (TSS) remained the weak spot, with segment net sales down 9% and Adjusted EBITDA down 30% on softer stationary air-conditioning aftermarket demand.
• You can dig deeper into the ticker's Major News, Today's Price Move, Price Targets, and Forecast on additional pages to track how this earnings event continues to shape the stock.
• For a broader view of the market, explore Trending AI Robots to see AI-driven trading strategies currently in focus.

Earnings Context and Why It Matters

The Chemours Company's third-quarter earnings report carries particular weight because it captures a portfolio pulling in opposite directions at once. Titanium Technologies is enjoying a pricing-led recovery in titanium dioxide (TiO2), while Advanced Performance Materials is riding demand from data-center and semiconductor end markets. At the same time, the high-margin Thermal & Specialized Solutions business is normalizing after an unusually strong prior-year quarter. For investors, this report is a key test of whether pricing gains and specialty growth can offset the cooling-market slowdown, while also shedding light on Chemours' balance-sheet progress, PFAS (per- and polyfluoroalkyl substances) liability overhang, and cash generation as the company works to reduce leverage.

Reported Results

For the third quarter ended September 30, 2026, Chemours reported net sales of $1.54 billion, a 3% increase from $1.50 billion in the prior-year quarter and essentially in line with consensus expectations. GAAP (generally accepted accounting principles) diluted EPS was $1.29, a sharp jump from $0.31 a year earlier, though the figure was heavily boosted by $150 million in PFAS insurance proceeds and a gain tied to the sale of the Kuan Yin property.

On an adjusted, non-GAAP basis, the picture was more subdued. Adjusted EPS of $0.21 rose 24% from $0.17 in the year-ago period but fell short of the roughly $0.26 to $0.27 consensus estimate. Adjusted EBITDA improved to $200 million from $189 million. The results reflected a strong Titanium Technologies quarter — net sales up 11% to $680 million and segment Adjusted EBITDA up to $85 million from $25 million — and an 8% sales gain in Advanced Performance Materials. These strengths were partially offset by a 9% decline in Thermal & Specialized Solutions net sales to $510 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Chemours and its specialty-chemicals peers, the AI Screener offers a structured way to surface relevant opportunities and monitor shifting sector conditions.

Market Reaction and Investor Sentiment

Initial market reaction to the report was muted to negative, with shares trading lower in the sessions following the release. While the headline GAAP EPS figure of $1.29 appeared to beat estimates, investors focused on the underlying adjusted EPS miss of $0.21 versus expectations near $0.26 to $0.27. The sequential revenue miss, driven largely by TSS weakness, and guidance for a seasonal fourth-quarter decline likely added to the cautious tone. Sentiment remains divided between optimism around TiO2 pricing momentum and the APM data-center/semiconductor growth story on one side, and concerns about cooling-market normalization, a softer macroeconomic backdrop, and an elevated leverage profile on the other.

Forward Outlook and Key Factors to Monitor

Chemours' guidance points to a seasonally softer fourth quarter. The company expects consolidated net sales to decline 5% to 10% sequentially and Adjusted EBITDA to land between $160 million and $185 million. For the full year 2026, management anticipates net sales growth of roughly 2% over 2025, with Adjusted EBITDA of $775 million to $800 million and capital expenditures of $220 million to $230 million.

Investors should watch several factors in the coming quarters. First, whether TiO2 pricing gains hold across regions will be critical to sustaining Titanium Technologies' margin recovery. Second, the durability of Advanced Performance Materials' order-book strength — particularly Performance Solutions products tied to data centers and semiconductors — will be a key growth indicator. Third, the pace of TSS normalization after the stationary air-conditioning technology transition under the U.S. AIM Act will help determine whether the segment's softness is temporary or more persistent.

On the financial side, progress on reducing net leverage — which management now expects to bring below 4.2x in 2026 — and continued free cash flow generation remain central. PFAS-related settlements and insurance recoveries will also continue to influence reported results and cash flows, making it important for investors to distinguish between one-time items and underlying operating performance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations